Electromed, Inc. (ELMD) Earnings Call Transcript
November 10, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for joining Electromed's first quarter fiscal 2027 earnings call. We released our quarterly results earlier today, and you can find them on the company website at www.smartvest.com. Before we begin, I want to remind all of you that certain statements management makes on this call are considered forward-looking statements, including statements regarding the company's future operating and financial results and plans. Those statements carry risks and uncertainties that could cause actual performance or achievements to differ materially from what is projected. Any such statements reflect management's expectations as of today's date. Please do not place undue reliance on these forward-looking statements, and the company undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise. For further guidance on this matter, please refer to the company's SEC filings. With me today are Jim Cunniff, Electromed's President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer. Jim will discuss the quarter's strategic and operating progress, Brad will cover the financial results and balance sheet, and after that we'll open the call to questions. With that, I'll now turn the call over to Jim Cunniff, President and Chief Executive Officer of Electromed.
Thanks, Mike, and good afternoon. Fiscal 2027 has begun, and the results from our first quarter offer a helpful signal about how the operational priorities we set at the start of the year are paying off. The first is broadening patient access. The second is extending the reach and productivity of our commercial organization. The third is turning sustained bronchiectasis awareness into SmartVest prescriptions. Our Q1 results show continued progress on that agenda. We posted Q1 fiscal year 2027 revenue growth of 10.6% along with operating income growth of 30.7%. That marks the 16th quarter in a row in which we have grown both revenue and operating income on a year-over-year basis. Net revenue for the first quarter came to $18.7 million, up 10.6% from the same quarter a year earlier. Operating income reached $3.5 million, versus $2.7 million in the first quarter of fiscal 2026, which shows how our team can pull operating leverage out of the business. We stay focused on profitable growth and disciplined investment, and that produced diluted earnings per share of $0.32, a 28% increase year over year from $0.25 in the prior year quarter. Looking by channel, our primary home care revenue rose 17.6% in the quarter compared with the prior year, helped by additional sales reps and better sales rep productivity. Distributor and hospital revenues fell 56% and 32%, respectively, against the prior year. This quarter's mix underscores why we run the business around sustained referral growth instead of the channel variability of any one period. Home care continues to be our main growth engine. It makes up 94% of our revenue and stays the central focus of our sales team, while the far smaller distributor and hospital channels offer additional ways to widen access to SmartVest. We finished the quarter with 63 direct home care sales representatives across four open territories. Our emphasis isn't just on adding territories; it's on recruiting effectively, onboarding well, and helping new representatives move toward full productivity. As of today's call, we have four strategic account managers working to create additional and durable demand for SmartVest in the hospital channel. On the hospital channel, we're excited to announce that we have renewed our contract with the largest hospital GPO in the country, giving their members access to SmartVest. Strategically, reaching the large scale of the bronchiectasis opportunity remains central to our strategy. Instead of repeating the market statistics we've shared before, I want to focus today on how we turn awareness into action, identifying appropriate patients earlier, helping clinicians evaluate airway clearance options, simplifying the prescription process, and expanding access through payer relationships. Our Triple Down on Bronchiectasis campaign keeps providing the clinical foundation for that work by stressing a three-part approach. One, clear the airways first. Two, treat the patient's infection. And three, reduce inflammation. During Q1, we moved our emphasis away from simply launching the framework and toward making it a more routine part of provider education and how we execute in the field. To build on that approach, we kicked off the Treat SMART from the Start campaign, giving clinicians a practical means of spotting when a patient's existing airway clearance method might not be enough and indicating that the moment may have arrived to prescribe SmartVest. Early feedback from providers has been encouraging, and we'll keep honing the program as we gain insight from how it performs in the field. When we're at medical conferences, people regularly ask us about the DPP-1 inhibitor that targets a patient's inflammation. Often the question is framed very specifically: does this drug take the place of airway clearance, or ought airway clearance to be continued alongside DPP-1 inhibitors? At a recent California Thoracic Society webinar called "Bronchiectasis: The Most Misunderstood Cough in the Room," a prominent pulmonologist and key opinion leader gave this answer, and I'm quoting: "We still recommend continuing airway clearance, and patients are continuing their airway clearance in addition to being put on a DPP-1 inhibitor." Put simply, DPP-1 inhibitors work in a complementary way with airway clearance rather than replacing it, because the drug doesn't clear the patient's lungs so that they can breathe more easily. Now I'd like to discuss some of the synergistic clinical and educational efforts we're undertaking. Across the first quarter, we ran four peer-to-peer programs in which roughly 400 clinicians took part. Each program shares the same objective: combine credible clinical education with a clear route for identifying and serving the right patients. Turning to evidence generation, a manuscript of ours, "Low Incidence of High-Frequency Chest Wall Oscillation in Bronchiectasis Registry Data Despite Indications and Reimbursement," appeared in the September issue of the COPD Foundation Journal. Drawing on data from the NTM Research Registry, the study determined that 58% of qualifying patients had not been prescribed HFCWO therapy, even though they satisfied every clinical criterion required for insurance coverage. This work matters because it helps clinicians spot the treatment gap and supports better-informed conversations about when HFCWO therapy might be appropriate. Our SmartOrder ePrescribe system keeps evolving from a differentiating capability into a key element of how we operate. The CMS administrative simplification rule that was recently finalized strengthens the shift toward electronic documentation and signatures rather than faxes, with compliance mandated by May 2028. During the first quarter, 48% of orders came in via SmartOrder, and those orders shipped about five days faster than orders submitted by fax. We're concentrating on driving adoption higher, since faster and cleaner submissions can enhance the experience for clinics, patients, and our reimbursement team. Payer access is still vital for reaching more eligible patients, and our team has made headway in reaching most covered lives in the U.S. As the quarter closed, 87% of covered lives in the U.S. were under contract, which reflects eight new or expanded agreements amounting to nearly 500,000 additional covered lives over the period. Beyond that headline coverage percentage, our team is working to boost contracting efficiency and make the patient experience more consistent across plans. Our manufacturing model based in the U.S. still helps us deliver dependable service and keep supply continuous. During Q1, we kept up our record for on-time deliveries as well as robust gross margins. The operations foundation we upgraded recently continues to be an important advantage as we scale. I also want to give recognition to the Electromed team for a strong start to fiscal 2027. Our people keep turning our mission into disciplined execution, and that link between employee engagement and customer service remains a meaningful strength. Before I hand the call over to Brad, I want to give you a brief update on the leadership transition we announced last quarter. As was announced, I expect to retire from the Chief Executive Officer role in April 2027. The board succession plan is underway, and we are approaching this transition with the same discipline we apply to operating the business. In the meantime, my priorities have not changed: execute our fiscal 2027 plan, support our team, and position the next leader for a smooth handoff. We have a clear strategy, a strong leadership group, and significant runway to expand access to SmartVest. My goal is to make sure that this performance continues and that my successor can step in seamlessly to work with this great team. Brad, over to you.
Thanks, Jim. Now for the quarter, I’ll walk through the main factors behind our first quarter results and where we stood financially on September 30, 2026. Except where I say otherwise, what I’ll cover compares the three months that ended September 30, 2026, against the three months that ended September 30, 2025. Net revenue for the first quarter came in at $18.7 million, up 10.6% from $16.9 million. Home care revenue rose 17.6% to $17.5 million. That revenue gain reflected more direct sales representatives as well as greater productivity among those representatives. On an annualized basis, home care revenue per weighted average direct sales representative reached $1,109,000 in Q1, slightly above the midpoint of the $1,050,000-$1,150,000 range we target for fiscal 2027. Non-home care revenue was $1.2 million versus $2.0 million in the same quarter a year earlier. The 41% drop in non-home care revenue came from a mix of two things: elevated distributor inventory in the market, which hurt the sales we make to our DME partners, and fewer capital sales into hospitals relative to the record hospital revenue we posted in Q1 last year. Gross profit was $14.9 million, equal to 80.0% of net revenue, compared with $13.2 million, or 78.1%, in the prior year quarter. The rise in gross profit dollars came from higher revenue, while the improvement in gross profit percentage came from revenue mix, as high-value home care revenue grew and lower-margin non-home care sales fell. Selling, general, and administrative, or SG&A, expenses totaled $11.2 million, up $0.9 million, or 8.6%. That increase was mainly attributable to higher salaries and incentive compensation tied to the greater average sales representative headcount, along with higher overall compensation costs. Operating income was $3.5 million, or 18.7% of net revenue, versus $2.7 million, or 15.8%, in the prior year quarter. Operating income growth of 30.7% stemmed primarily from the increases in revenue and gross profit. Net income for the first quarter was $2.8 million, with diluted earnings per share of $0.32, compared with $2.1 million, or $0.25, last year. At September 30, 2026, Electromed held $15.9 million in cash and $30.3 million in accounts receivable, carried no debt, and achieved working capital of $44.9 million along with shareholders’ equity of $52.5 million. The cash balance represents a $4.6 million decrease for Q1, versus a $1.2 million decrease in cash during the same period a year earlier. The cash decrease for the three months ended September 30, 2026, was driven mainly by repurchases of Electromed common stock totaling $4.3 million. In summary, Q1 showed our disciplined execution and operating leverage even as we kept investing in the capabilities required for future growth. We stay focused on serving more patients, supporting our commercial organization, and turning revenue growth into sustainable earnings and cash flow. With that, operator, please open the call to questions.
Good afternoon, gentlemen. Am I coming through clearly on your end?
Yes, we hear you fine. Thanks.
All right, seems like there's some music playing. Not sure whether I got dropped into the queue or what. Just quickly, regarding the home care distributor revenue, that impact you've been seeing, when do you think it'll return to more normalized levels, and how many DMEs that you work with is this affecting?
Yeah, great question, Ben. I believe we covered that last quarter and once more in the prepared comments we made. Honestly, my expectation is that we likely won't see a rebound until the start of the calendar year. From my conversations with our DME partners, one thing they're grappling with right now is their inventory position relative to their customer demand. I think you'll find that some of them are carrying too much inventory of various HFCWO devices compared with the demand they have, but they do expect that to ease probably at the beginning of next calendar year.
All right, understood. Sorry I missed that part in the prepared remarks. So just your thinking, then, on replenishing the buyback here, and I believe the credit facility you have runs out in a few weeks, unless I'm wrong about that. Any view on that?
Yes, thanks for asking, Ben. By the end of the quarter, we had used $8.2 million out of the $10 million authorization we set up last year. I can't comment on what happens in future periods, but as we've said before, when we look at how to use cash, we'll do whatever drives the greatest shareholder value, which includes investing in the business and also weighing future share repurchases.
All right, that's fair. Appreciate you taking the question, gentlemen.
Thanks, operator. Before wrapping up the call, I'd like to leave you with a few key takeaways from this quarter. To sum up, the first quarter of fiscal 2027 showed continued growth and operating leverage at Electromed, with positive momentum in home care, measurable progress in SmartOrder adoption, and disciplined investment in the sales force. With a strong balance sheet and a focused strategy, we believe Electromed is well-positioned to build on this start over the balance of the year. As always, thank you for joining us today. Should you have questions or want to schedule a call with the Electromed team following today's report, please reach out to our investor relations partners at ICR Healthcare. Operator, with that, please close the call.
That brings us to the end of today's teleconference. At this point you're welcome to disconnect your line, and we appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Electromed, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Electromed, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.